# CodeBreaK 201 (NCT04933695)

> A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

No report yet. It can be ordered.

- Drugs tested: sotorasib
- Indication: first-line KRAS G12C stage IV NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04933695
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Amgen
- Conditions: Non-small Cell Lung Cancer
- Interventions: Sotorasib
- Enrollment: 42
- Primary outcome: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on CodeBreaK 201 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=codebreak-201-nct04933695